d o i : 1 0 . 1 1 1 1 / j . 1 3 6 8 - 5 0 3 1 . 2 0 0 5 . 0 0 4 9 2 . xThe participation of health professionals in a smoking-cessationprogramme positively influences the smoking cessation advicegiven to patientsP . M . J . P U S K A , 1 M . B A R R U E C O , 2 C . R O U S S O S , 3 A . H I D E R , 4 S . H O G U E 5National Public Health Institute,1 Helsinki, Finland, Salamanca University,2 Sa
Wcsr.comMary W. Bourke
Mary Bourke is a Partner in Womble Carlyle’s Intellectual Property Practice Group
in the firm’s Wilmington, Delaware office. She represents clients in patent
litigation related to biotechnology and pharmaceutical matters.
Mary has over 25 years of patent litigation experience at both the district court and
appellate levels. She has been involved in multiple ANDA litigations and is
knowledgeable about the complexities of litigation under the Hatch-Watchman Act. She was the co-first chair for Pfizer’s successful defense of Lipitor® against several ANDA filers. Additionally, Mary currently represents Astra Zeneca in multiple Areas of Practice
litigations involving AstraZeneca’s successful drug CRESTOR®. Mary also successfully led the litigation team for Lifescan Inc. in an infringement action filed against it and four other competitors by Roche relating to blood glucose Mary has experience in all phases of litigation including pretrial, trial and appellate Contact Information
stages, both domestically and internationally. She also participates in due diligence activities for major pharmaceutical companies. In 2010, Mary was recognized as one of the world’s leading life sciences patent litigators by IAM (Intellectual Asset Management) magazine. Representative Cases
Palmetto Pharmaceuticals LLC v. AstraZeneca Pharmaceuticals LP (D.
AstraZeneca UK Limited et al v. Watson Pharmaceuticals Inc. et al (D.
Salix Pharmaceuticals, Inc. and Dr. Falk Pharma GmbH v. Lupin
Limited and Lupin Pharmaceuticals, Inc. (D. Del.) (APRISO®) Roche Diagnostics Operations, Inc., et al v. Abbott Diabetes Care, et al. (LifeScan Inc.) (D.Del.) (One Touch Ultra®)
Novartis Vaccines & Diagnostics, Inc. v. MedImmune, LLC, et al (D.
In re Armodafanil Patent Litigation (Cephalon Inc., et al) (D. Del.)
In re: Rosuvastatin Calcium Patent Litigation, (AstraZeneca
Pharmaceuticals LP et al) (Fed. Cir.)
Purdue Pharma Products LP et al (Ortho-McNeil) v. Par Pharmaceuticals
The Brigham and Women’s Hospital, Inc., NPS Pharmaceuticals, Inc. and
Amgen Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Barr Laboratories, Inc. (D. Del.) (SENSIPAR®) Pfizer Inc. v. Ranbaxy Labs, Ltd. (Fed. Cir.) (LIPITOR®)
Bayer AG v. Biovail Corporation (Fed. Cir.) (PROCARDIA®)
Bayer AG and Bayer Corporation v. Housey Pharmaceuticals, Inc. (Cell
Talecris and Bayer v. Baxter International, et al (D. Del.)
Admitted to bar: 1985, Delaware.
Admitted to practice before the U.S. District Court for District of Delaware, 1987;
U.S. Court of Appeals for the Third Circuit, 1987; and the U.S. Court of Appeals
for the Federal Circuit, 1987.
B.S.E, 1981, Princeton University, with Honors;
J.D., 1984, University of Pittsburgh School of Law.
Prior Legal Experience
Partner, Connolly Bove Lodge & Hutz LLP, Wilmington, Delaware.
Barriär- Lösenpris Elasticitet per aktie AstraZeneca – tre faktorer som talar för kursuppgång Aktien har backat med mer än 10 procent sedan årsskiftet, huvudsakligen till följd av oro över risken för lanseringar av generika i USA för AstraZenecas läkemedel Seroquel och Nexium. Även om vi finner det osannolikt att både Seroquel och Nexium skulle förlora